Skip to main content

Table 1 Participant characteristics at baseline

From: A novel Aβ isoform pattern in CSF reflects γ-secretase inhibition in Alzheimer disease

 

Placebo

LY450139, 100 mg

LY450139, 140 mg

Characteristic

( n = 10)

( n = 15)

( n = 10)

Demographics

   

Age, mean (SD, years)

69.1 (8.81)

72.4 (8.13)

68.8 (9.02)

Female sex, number (%)

5 (50)

10 (66.6)

4 (40)

APOE e4 carriers, number (%)

8 of 10 (80)

11 of 13 (84.6)

7 of 9 (77.8)

Clinical scores, mean (SD)

   

MMSE

18.3 (4.0)

22 (3.6)

24.9 (1.4)

ADCS-ADL

61.9 (7.3)

67.7 (8.4)

70.6 (7.8)

ADAS-Cog 11

26.9 (10.0)

19.9 (6.3)

17.9 (5.8)

  1. ADAS-Cog 11, Alzheimer's Disease Assessment Scale Cognitive Subscale; ADCS-ADL, Alzheimer's Disease Cooperative Study Activities of Daily Living Scale; APOE, apolipoprotein E; MMSE, Mini-Mental State Examination.